Icosavax Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-96.71	-91.76	-66.97	-18.85	-5.97
Depreciation & Amortization	2.95	1.84	0.08	0	0
Share-Based Compensation	25.07	21.69	29.03	0.26	0.07
Other Operating Activities	-0.16	6.55	-0.68	4.39	0.66
Operating Cash Flow	-68.85	-61.68	-38.54	-14.21	-4.57
Capital Expenditures	-4.83	-11.11	-1.01	-0.01	0
Change in Investments	-4.08	-158.34	0	0	0
Other Investing Activities	-2.63	-	-	-	-
Investing Cash Flow	-11.55	-169.45	-1.01	-0.01	0
Share Issuance / Repurchase	77.71	10.31	191.14	0.17	0.24
Debt Issued / Paid	0	0	0	6.46	0
Other Financing Activities	0.36	-	113.63	-	26.5
Financing Cash Flow	78.07	10.31	304.77	6.64	26.74
Net Cash Flow	-2.33	-220.82	265.23	-7.58	22.17
Free Cash Flow	-73.68	-72.79	-39.55	-14.22	-4.57
Free Cash Flow Margin	-	-12506.53%	-506.87%	-879.89%	-
Free Cash Flow Per Share	-1.47	-1.83	-2.20	-6.33	-0.69

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).